# A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

> **NCT00605280** · PHASE2,PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 317 (actual)

## Conditions studied

- Macular Edema Associated With Diabetes Mellitus

## Interventions

- **DRUG:** Standard of Care
- **DRUG:** Macugen

## Key facts

- **NCT ID:** NCT00605280
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2009-11
- **Final completion:** 2011-07
- **Target enrollment:** 317 (ACTUAL)
- **Last updated:** 2018-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00605280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00605280, "A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00605280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*